Pantoprazole in Cisplatin Nephrotoxicity
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
1 other identifier
interventional
60
1 country
1
Brief Summary
Pantoprazole in Cisplatin Nephrotoxicity
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started May 2019
Longer than P75 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2019
CompletedFirst Submitted
Initial submission to the registry
December 29, 2019
CompletedFirst Posted
Study publicly available on registry
January 3, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2030
January 3, 2020
January 1, 2020
11.6 years
December 29, 2019
January 2, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Number of patients with no renal toxicity
The number of patients with no renal toxicity
6 months
Study Arms (3)
Standard hydration alone
ACTIVE COMPARATORCisplatin with standard hydration
Pantoprazole high dose
ACTIVE COMPARATORCisplatin with standard hydration with pantoprazole 1.6 mg/kg
Pantoprazole Low dose
ACTIVE COMPARATORCisplatin with standard hydration with pantoprazole 0.6 mg/kg
Interventions
Pantoprazole 1.6 mg\\kg
Standard hydration alone
Eligibility Criteria
You may qualify if:
- Patients with head and neck cancer
You may not qualify if:
- GFR less than 59.
- Elevated liver enzymes more than 3 fold.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sherief Abd-Elsalam
Tanta, Egypt
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eman M Ghonaim, Msc
Demonstrator of Clinical Pharmacy
- PRINCIPAL INVESTIGATOR
Sahar El-Haggar, Prof
Tanta University
- PRINCIPAL INVESTIGATOR
Suzy Goher, Lecturer
Tanta University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Ass. Prof. Tropical Medicine
Study Record Dates
First Submitted
December 29, 2019
First Posted
January 3, 2020
Study Start
May 1, 2019
Primary Completion (Estimated)
December 1, 2030
Study Completion (Estimated)
December 30, 2030
Last Updated
January 3, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will not share